300181 佐力药业
已收盘 05-13 15:00:00
资讯
新帖
简况
东吴证券:给予佐力药业买入评级
证券之星 · 04-28
东吴证券:给予佐力药业买入评级
【4月25日两融净买入前十:招商蛇口(2.01亿元)、比亚迪(1.94亿元)】沪深两市数据显示,4月25日,融资净买入前十的股票分别为:招商蛇口(2.01亿元)、比亚迪(1.94亿元)、拓维信息(1.72亿元)、寒武纪(1.69亿元)、浙江荣泰(1.58亿元)、佐力药业(1.56亿元)、指南针(1.48亿元)、天富能源(1.28亿元)、中油资本(1.27亿元)、振华股份(1.19亿元)。
金融界 · 04-28
【4月25日两融净买入前十:招商蛇口(2.01亿元)、比亚迪(1.94亿元)】沪深两市数据显示,4月25日,融资净买入前十的股票分别为:招商蛇口(2.01亿元)、比亚迪(1.94亿元)、拓维信息(1.72亿元)、寒武纪(1.69亿元)、浙江荣泰(1.58亿元)、佐力药业(1.56亿元)、指南针(1.48亿元)、天富能源(1.28亿元)、中油资本(1.27亿元)、振华股份(1.19亿元)。
开源证券:给予佐力药业买入评级
证券之星 · 04-26
开源证券:给予佐力药业买入评级
佐力药业(300181)2025年一季报简析:营收净利润同比双双增长,应收账款上升
证券之星 · 04-25
佐力药业(300181)2025年一季报简析:营收净利润同比双双增长,应收账款上升
图解佐力药业一季报:第一季度单季净利润同比增27.20%
证券之星 · 04-24
图解佐力药业一季报:第一季度单季净利润同比增27.20%
图解佐力药业年报:第四季度单季净利润同比减10.18%
证券之星 · 04-24
图解佐力药业年报:第四季度单季净利润同比减10.18%
佐力药业,中药集采后三年高增
Ofweek维科网 · 04-16
佐力药业,中药集采后三年高增
佐力药业:预计2025年1-3月归属净利润盈利1.78亿元至1.89亿元
证券之星 · 03-09
佐力药业:预计2025年1-3月归属净利润盈利1.78亿元至1.89亿元
佐力药业预计2025年1-3月净利润盈利17,800万元至18,900万元,同比上年增长24.99%至32.71%
金融界 · 03-09
佐力药业预计2025年1-3月净利润盈利17,800万元至18,900万元,同比上年增长24.99%至32.71%
佐力药业最新公告:一季度净利同比预增24.99%—32.71% 董事长提议2024年度10派6元
证券之星 · 03-09
佐力药业最新公告:一季度净利同比预增24.99%—32.71% 董事长提议2024年度10派6元
【佐力药业:一季度净利同比预增24.99%—32.71% 董事长提议2024年度10派6元】佐力药业(300181.SZ)发布业绩预告,预计2025年第一季度1.78亿元—1.89亿,同比增长24.99%—32.71%。佐力药业同日公告,公司控股股东、实际控制人、董事长俞有强提议公司未来实施2024年度权益分派方案,向全体股东每10股派发现金股利6元(含税),不送红股,也不以资本公积金转增股本。
金融界 · 03-09
【佐力药业:一季度净利同比预增24.99%—32.71% 董事长提议2024年度10派6元】佐力药业(300181.SZ)发布业绩预告,预计2025年第一季度1.78亿元—1.89亿,同比增长24.99%—32.71%。佐力药业同日公告,公司控股股东、实际控制人、董事长俞有强提议公司未来实施2024年度权益分派方案,向全体股东每10股派发现金股利6元(含税),不送红股,也不以资本公积金转增股本。
佐力药业(300181.SZ)发预增,预计一季度归母净利润1.78亿元-1.89亿元,同比增长24.99%-32.71%
智通财经 · 03-09
佐力药业(300181.SZ)发预增,预计一季度归母净利润1.78亿元-1.89亿元,同比增长24.99%-32.71%
佐力药业(300181.SZ)2024年度归母净利润5.05亿元,同比增长31.79%
智通财经 · 03-09
佐力药业(300181.SZ)2024年度归母净利润5.05亿元,同比增长31.79%
佐力药业(300181.SZ)控股股东、实控人提议2024年度每10股派6元
智通财经 · 03-09
佐力药业(300181.SZ)控股股东、实控人提议2024年度每10股派6元
佐力药业(300181.SZ):一季度净利润同比预增24.99%-32.71%
格隆汇 · 03-09
佐力药业(300181.SZ):一季度净利润同比预增24.99%-32.71%
佐力药业(300181.SZ):2024年度净利润5亿元,同比增长31.79%
格隆汇 · 03-09
佐力药业(300181.SZ):2024年度净利润5亿元,同比增长31.79%
佐力药业2024年1-12月营业收入为25.8亿元,较去年同期增长32.81%
金融界 · 03-09
佐力药业2024年1-12月营业收入为25.8亿元,较去年同期增长32.81%
佐力药业发布2024年度业绩快报,盈利5.047亿元,低于分析师预期
证券之星 · 03-09
佐力药业发布2024年度业绩快报,盈利5.047亿元,低于分析师预期
佐力药业:2月21日组织现场参观活动,包括知名机构聚鸣投资,盘京投资的多家机构参与
证券之星 · 02-24
佐力药业:2月21日组织现场参观活动,包括知名机构聚鸣投资,盘京投资的多家机构参与
【机构调研记录】诺德基金调研佐力药业
证券之星 · 02-24
【机构调研记录】诺德基金调研佐力药业
加载更多
公司概况
公司名称:
浙江佐力药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-02-22
主营业务:
浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵胶囊、灵泽片、灵莲花颗粒、百令片、百令胶囊、中药饮片及中药配方颗粒、聚卡波非钙片。公司核心产品乌灵胶囊入选浙江省首批“浙产名药”、首批“浙产中药”产业品牌,入选由中国中医药循证医学中心发布的全国首批100个基于评价证据的中药品种目录。2024年2月,乌灵胶囊和灵泽片获评浙江省经济和信息化厅等八部门发布的首批“浙产中药”产业品牌名单。2024年3月,广东省交易控股集团指导,广东省药品交易中心主办的第九届中国药品交易年会召开,乌灵胶囊荣登“2023年最具影响力中成药产品十强榜”榜单。2024年5月,“强基层新征程”第十一届中国县域卫生发展大会召开,公司荣获2023-2024年度“赋能县域医疗高质量发展卓越品牌企业”,持续助力中国县域卫生发展。2024年6月,由米内网发起主办的“2023年度中国医药工业百强系列榜单”对外公布,公司位列“2023年度中国医药工业百强系列榜单”子榜单“2023年度中国中药企业TOP100排行榜”第48名。2024年6月,浙江省经济和信息化厅发布了《2023年度浙江省生物医药产业重点企业名单(领军型和高成长型)》,公司荣获“浙江省生物医药产业领军型企业”称号。2024年7月,由中国非处方药物协会、中国医药新闻信息协会与新华大健康联合主办的“中国第七届OTC品牌宣传月”启动,乌灵胶囊入选“中国第七届OTC品牌宣传月”宣传品牌。2024年8月,由中康科技主办的第十七届西普会,乌灵胶囊荣登2024年健康产业品牌榜,获得“西普金奖”。2024年11月,第三届泰山医药论坛暨2023-2024年度医药行业信息发布会召开,公司荣获2023-2024年度医药行业增长率前五十家企业和2023-2024年度制药工业营业收入前百家企业两项奖项。2024年11月,由家庭医生在线发起“2023-2024家庭常备药、家庭常备营养保健品、家庭常备医疗器械及消毒用品上榜品牌”颁奖典礼,乌灵胶囊荣登“家庭常备安神助眠药”“家庭常备老年认知障碍用药”及“家庭常备增强记忆用药”三大品牌榜单,并荣获最佳人气奖称号。2024年12月,由中国非处方药物协会主办的以“相信品牌的力量”为主题的第二届OTC品牌大会召开,乌灵胶囊荣获“2024年度中国非处方药黄金大单品”“中成药•头痛失眠类第二名”重要奖项。
发行价格:
23.50
{"stockData":{"symbol":"300181","market":"SZ","secType":"STK","nameCN":"佐力药业","latestPrice":16.17,"timestamp":1747119807000,"preClose":16.1,"halted":0,"volume":11664630,"delay":0,"changeRate":0.0043,"floatShares":603000000,"shares":701000000,"eps":0.7792,"marketStatus":"已收盘","change":0.07,"latestTime":"05-13 15:00:00","open":16.19,"high":16.23,"low":16.05,"amount":188000000,"amplitude":0.0112,"askPrice":16.17,"askSize":827,"bidPrice":16.16,"bidSize":613,"shortable":0,"etf":0,"ttmEps":0.7792,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747186200000},"marketStatusCode":5,"adr":0,"adjPreClose":16.1,"symbolType":"stock","openAndCloseTimeList":[[1747099800000,1747107000000],[1747112400000,1747119600000]],"highLimit":17.71,"lowLimit":14.49,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":701387335,"isCdr":false,"pbRate":3.62,"roa":"--","peRate":20.752053,"roe":"6.34%","epsLYR":0.73,"committee":-0.248844,"marketValue":11341000000,"turnoverRate":0.0193,"status":0,"floatMarketCap":9749000000},"requestUrl":"/m/hq/s/300181","defaultTab":"news","newsList":[{"id":"2530100954","title":"东吴证券:给予佐力药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2530100954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530100954?lang=zh_cn&edition=full","pubTime":"2025-04-28 14:05","pubTimestamp":1745820328,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对佐力药业进行研究并发布了研究报告《2024年报&2025一季报点评,盈利能力稳健提升,收入及利润创单季度新高》,给予佐力药业买入评级。公司紧抓集采机遇,深耕等级医院及基层市场开拓,积极往OTC拓展,业绩增速可期,同时保持较高的分红率,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级4家,增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800016546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","601555"],"gpt_icon":0},{"id":"2530493062","title":"【4月25日两融净买入前十:招商蛇口(2.01亿元)、比亚迪(1.94亿元)】沪深两市数据显示,4月25日,融资净买入前十的股票分别为:招商蛇口(2.01亿元)、比亚迪(1.94亿元)、拓维信息(1.72亿元)、寒武纪(1.69亿元)、浙江荣泰(1.58亿元)、佐力药业(1.56亿元)、指南针(1.48亿元)、天富能源(1.28亿元)、中油资本(1.27亿元)、振华股份(1.19亿元)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530493062","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530493062?lang=zh_cn&edition=full","pubTime":"2025-04-28 09:07","pubTimestamp":1745802455,"startTime":"0","endTime":"0","summary":"沪深两市数据显示,4月25日,融资净买入前十的股票分别为:招商蛇口(2.01亿元)、比亚迪(1.94亿元)、拓维信息(1.72亿元)、寒武纪(1.69亿元)、浙江荣泰(1.58亿元)、佐力药业(1.56亿元)、指南针(1.48亿元)、天富能源(1.28亿元)、中油资本(1.27亿元)、振华股份(1.19亿元)。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/28090749936349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0077","LU0164872284.USD","BK0049","LU0511384066.AUD","LU0819121731.USD","603119","002594","300181","LU0348735423.USD","LU0708995583.HKD","LU0289961442.SGD","002261","BK1515","BK0094","LU0320764599.SGD","BK0188","603067","BK0144","01211","BK0276","EVS.SI","600509","BK0239","BK0052","81211","LU0289960550.SGD","000617","LU1242518857.USD","LU0463099449.HKD","688256","BK0235","LU0588545490.SGD","159982","LU0588546209.SGD","BK0229","300803","LU1997245094.SGD","BK0007","001979","LU0175139822.USD","BK0272","LU2289578879.USD","HYDD.SI","BYDDY","BK0155","LU0509642566.USD","LU0359201612.USD","LU1969619763.USD","399300"],"gpt_icon":0},{"id":"2530119026","title":"开源证券:给予佐力药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2530119026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530119026?lang=zh_cn&edition=full","pubTime":"2025-04-26 10:40","pubTimestamp":1745635226,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,巢舒然近期对佐力药业进行研究并发布了研究报告《公司信息更新报告:2024营收利润增长亮眼,营销发力强化品牌护城河》,给予佐力药业买入评级。 佐力药业 营收利润增长亮眼,维持“买入”评级 公司2024年实现营收25.78亿元;归母净利润5.08亿元;扣非归母净利润5.08亿元。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级4家,增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600009794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300181"],"gpt_icon":0},{"id":"2530363191","title":"佐力药业(300181)2025年一季报简析:营收净利润同比双双增长,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2530363191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530363191?lang=zh_cn&edition=full","pubTime":"2025-04-26 06:37","pubTimestamp":1745620644,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期佐力药业发布2025年一季报。截至本报告期末,公司营业总收入8.24亿元,同比上升22.52%,归母净利润1.81亿元,同比上升27.2%。本报告期佐力药业应收账款上升,应收账款同比增幅达34.77%。去年的净利率为20.01%,算上全部成本后,公司产品或服务的附加值高。持有佐力药业最多的基金为富国精准医疗混合A,目前规模为37.46亿元,最新净值2.7847,较上一交易日下跌2.39%,近一年上涨28.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600007297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181"],"gpt_icon":0},{"id":"2530696107","title":"图解佐力药业一季报:第一季度单季净利润同比增27.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530696107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530696107?lang=zh_cn&edition=full","pubTime":"2025-04-25 03:01","pubTimestamp":1745521310,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业2025年一季报显示,公司主营收入8.24亿元,同比上升22.52%;归母净利润1.81亿元,同比上升27.2%;扣非净利润1.81亿元,同比上升26.16%;负债率30.38%,投资收益-29.3万元,财务费用133.06万元,毛利率60.9%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500001590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181"],"gpt_icon":0},{"id":"2530968342","title":"图解佐力药业年报:第四季度单季净利润同比减10.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530968342","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530968342?lang=zh_cn&edition=full","pubTime":"2025-04-25 01:10","pubTimestamp":1745514653,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业2024年年报显示,公司主营收入25.78亿元,同比上升32.71%;归母净利润5.08亿元,同比上升32.6%;扣非净利润5.08亿元,同比上升35.89%;其中2024年第四季度,公司单季度主营收入5.33亿元,同比上升11.62%;单季度归母净利润8629.18万元,同比下降10.18%;单季度扣非净利润9261.67万元,同比下降0.17%;负债率29.37%,投资收益-66.21万元,财务费用-650.74万元,毛利率60.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500000780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181"],"gpt_icon":0},{"id":"2527237134","title":"佐力药业,中药集采后三年高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2527237134","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527237134?lang=zh_cn&edition=full","pubTime":"2025-04-16 14:38","pubTimestamp":1744785491,"startTime":"0","endTime":"0","summary":"少部分企业却能化政策挑战为增长机遇,比如佐力药业在中药集采的影响下,反而越战越勇。佐力药业的核心产品乌灵胶囊在2022年首次接触集采,此后三年公司业绩一直保持快速增长。乌灵胶囊用药频度和用药金额持续增长且处于首位,临床使用率高。2020年,佐力药业迎来第一个转折。同年,佐力药业完成对亏损子公司百草中药的股权处置,甩掉历史包袱。这些情况给予了佐力药业以量换价的操作空间。但从佐力药业来看,它是准备好了。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041614391894d70f18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041614391894d70f18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0042","300181","562390","BK0077","BK0239","561510"],"gpt_icon":0},{"id":"2518401927","title":"佐力药业:预计2025年1-3月归属净利润盈利1.78亿元至1.89亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518401927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518401927?lang=zh_cn&edition=full","pubTime":"2025-03-09 18:00","pubTimestamp":1741514440,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业发布业绩预告,预计2025年1-3月归属净利润盈利1.78亿元至1.89亿元。中药配方颗粒随 着备案品种增加,同比持续增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030900002931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181"],"gpt_icon":0},{"id":"2518406307","title":"佐力药业预计2025年1-3月净利润盈利17,800万元至18,900万元,同比上年增长24.99%至32.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518406307","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518406307?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:32","pubTimestamp":1741509133,"startTime":"0","endTime":"0","summary":"佐力药业公告称,预计2025年1-3月扣除非经常性损益后的净利润盈利:17,780万元至18,980万元,同比上年增长:23.79%至32.14%。中药配方颗粒随着备案品种增加,同比持续增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/09163248614802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300181"],"gpt_icon":0},{"id":"2518405741","title":"佐力药业最新公告:一季度净利同比预增24.99%—32.71% 董事长提议2024年度10派6元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518405741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518405741?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:30","pubTimestamp":1741509035,"startTime":"0","endTime":"0","summary":"佐力药业(300181.SZ)发布业绩预告,预计2025年第一季度1.78亿元—1.89亿,同比增长24.99%—32.71%。佐力药业同日公告,公司控股股东、实际控制人、董事长俞有强提议公司未来实施2024年度权益分派方案,向全体股东每10股派发现金股利6元(含税),不送红股,也不以资本公积金转增股本。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030900002663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0042","BK0239","BK0077"],"gpt_icon":0},{"id":"2518406582","title":"【佐力药业:一季度净利同比预增24.99%—32.71% 董事长提议2024年度10派6元】佐力药业(300181.SZ)发布业绩预告,预计2025年第一季度1.78亿元—1.89亿,同比增长24.99%—32.71%。佐力药业同日公告,公司控股股东、实际控制人、董事长俞有强提议公司未来实施2024年度权益分派方案,向全体股东每10股派发现金股利6元(含税),不送红股,也不以资本公积金转增股本。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518406582","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518406582?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:30","pubTimestamp":1741509031,"startTime":"0","endTime":"0","summary":"佐力药业(300181.SZ)发布业绩预告,预计2025年第一季度1.78亿元—1.89亿,同比增长24.99%—32.71%。佐力药业同日公告,公司控股股东、实际控制人、董事长俞有强提议公司未来实施2024年度权益分派方案,向全体股东每10股派发现金股利6元(含税),不送红股,也不以资本公积金转增股本。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/09163048614784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","300181","BK0077","BK0042"],"gpt_icon":0},{"id":"2518405773","title":"佐力药业(300181.SZ)发预增,预计一季度归母净利润1.78亿元-1.89亿元,同比增长24.99%-32.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518405773","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518405773?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:30","pubTimestamp":1741509012,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佐力药业(300181.SZ)发布2025年第一季度业绩预告,公司预计第一季度归属于上市公司股东的净利润1.78亿元-1.89亿元,同比增长24.99%-32.71%。报告期内公司基于乌灵胶囊、百令片、灵泽片三个核心产品是国家基本药物目录产品的优势,持续加强市场拓展,取得了一定的增长。中药配方颗粒随着备案品种增加,同比持续增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300181"],"gpt_icon":0},{"id":"2518405778","title":"佐力药业(300181.SZ)2024年度归母净利润5.05亿元,同比增长31.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518405778","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518405778?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:24","pubTimestamp":1741508671,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佐力药业 发布2024年度业绩快报,公司2024年度营业总收入25.8亿元,同比增长32.81%;归属于上市公司股东的净利润5.05亿元,同比增长31.79%;扣除非经常性损益后的归属于上市公司股东的净利润5.03亿元,同比增长34.75%;基本每股收益0.72元。子公司佐力医药实现新增营业收入15,776.86万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300181"],"gpt_icon":0},{"id":"2518057754","title":"佐力药业(300181.SZ)控股股东、实控人提议2024年度每10股派6元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518057754","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518057754?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:20","pubTimestamp":1741508430,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佐力药业(300181.SZ)公告,公司董事会于2025年3月6日收到公司控股股东、实际控制人、董事长俞有强出具的《关于浙江佐力药业股份有限公司2024年度利润分配预案的提议和承诺》,俞有强提议:以公司未来实施2024年年度权益分派方案时股权登记日的总股本(剔除公司回购专用证券账户持有股份数量)为基数,向全体股东每10股派发现金股利人民币6.00元(含税),不送红股,也不以资本公积金转增股本。若以截至2025年2月28日总股本701,387,335股剔除公司回购专用证券账户持有股份数量8,920,074股为基数测算,预计派发现金股利共计415,480,356.6元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0042","BK0077","300181"],"gpt_icon":0},{"id":"2518054974","title":"佐力药业(300181.SZ):一季度净利润同比预增24.99%-32.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518054974","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518054974?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:06","pubTimestamp":1741507589,"startTime":"0","endTime":"0","summary":"格隆汇3月9日丨佐力药业(300181.SZ)公布2025年第一季度业绩预告,预计2025年1月1日至2025年3月31日归属于上市公司股东的净利润17,800万元-18,900万元,同比增长24.99%-32.71%;扣除非经常性损益后的净利润17,780万元-18,980万元,同比增长23.79%-32.14%。报告期内公司基于乌灵胶囊、百令片、灵泽片三个核心产品是国家基本药物目录产品的优势,持续加强市场拓展,取得了一定的增长。中药配方颗粒随着备案品种增加,同比持续增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/09160648614748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300181"],"gpt_icon":0},{"id":"2518382405","title":"佐力药业(300181.SZ):2024年度净利润5亿元,同比增长31.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518382405","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518382405?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:04","pubTimestamp":1741507463,"startTime":"0","endTime":"0","summary":"格隆汇3月9日丨佐力药业(300181.SZ)公布2024年度业绩快报,本报告期内,公司实现营业总收入25.8亿元,较上年同期增长32.81%;实现归属于上市公司股东的净利润5亿元,较上年同期增长31.79%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/09160448614749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"佐力药业(300181.SZ):2024年度净利润5亿元,同比增长31.79%","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300181"],"gpt_icon":0},{"id":"2518053054","title":"佐力药业2024年1-12月营业收入为25.8亿元,较去年同期增长32.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518053054","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518053054?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:02","pubTimestamp":1741507336,"startTime":"0","endTime":"0","summary":"佐力药业发布公告称,2024年1-12月公司营业总收入为25.8亿元,较去年同期增长32.81%,净利润为5.05亿,较去年同期增长31.79%,每股收益0.72元,每股净资产3.95元,净资产收益率为18.45%,所处行业为中药。资料显示,佐力药业成立于2000年,位于浙江省德清县阜溪街道志远北路388号,是一家以从事药品的研发、生产和销售为主的企业。企业注册资本7.01亿人民币,法人代表为汪涛。通过天眼查大数据分析,浙江佐力药业股份有限公司共对外投资了8家企业,参与招投标项目4922次;知识产权方面有商标信息98条,专利信息33条;此外企业还拥有行政许可130个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/09160248614731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300181"],"gpt_icon":0},{"id":"2518403214","title":"佐力药业发布2024年度业绩快报,盈利5.047亿元,低于分析师预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2518403214","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518403214?lang=zh_cn&edition=full","pubTime":"2025-03-09 15:41","pubTimestamp":1741506072,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业近日即将发布2024年年报,根据3月9日发布的业绩快报,归属净利润盈利5.047亿元,同比增长31.79%。子公司佐力医药实现新增营业收入15,776.86万元。证券之星数据中心根据近三年发布的研报数据计算,长城证券袁紫馨研究员团队对该股研究较为深入,近三年预测准确度均值高达99.2%,其预测佐力药业2024年度归属净利润为盈利5.57亿元,根据现价换算的预测PE为18.67。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030900002472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0042","BK0239","300181"],"gpt_icon":0},{"id":"2513980747","title":"佐力药业:2月21日组织现场参观活动,包括知名机构聚鸣投资,盘京投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2513980747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513980747?lang=zh_cn&edition=full","pubTime":"2025-02-24 10:01","pubTimestamp":1740362478,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年2月21日佐力药业发布公告称公司于2025年2月21日组织现场参观活动,重阳投资、聚鸣投资、盘京投资、UBS、Springhill、HCHP 管理、清池资本、三井住友资管参与。佐力药业主营业务:药品的研发、生产和销售。该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022400004942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300181","BK0042","BK0239"],"gpt_icon":0},{"id":"2513676169","title":"【机构调研记录】诺德基金调研佐力药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2513676169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513676169?lang=zh_cn&edition=full","pubTime":"2025-02-24 08:04","pubTimestamp":1740355448,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及2月21日披露的机构调研信息,诺德基金近期对1家上市公司进行了调研,相关名单如下:1)佐力药业 调研纪要:佐力药业在医药市场变化下,通过以价换量、加速医院覆盖、拓展院外市场、新媒体平台宣传等措施应对。乌灵胶囊作为独家产品,具有高安全性、高临床认可度和合理的日均用药成本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022400001673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","300181","BK0042"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1747134066152,"stockEarnings":[{"period":"1week","weight":0.0281},{"period":"1month","weight":-0.0225},{"period":"3month","weight":0.1165},{"period":"6month","weight":-0.064},{"period":"1year","weight":0.0438},{"period":"ytd","weight":0.0482}],"compareEarnings":[{"period":"1week","weight":0.0275},{"period":"1month","weight":0.0405},{"period":"3month","weight":0.0154},{"period":"6month","weight":-0.0204},{"period":"1year","weight":0.0681},{"period":"ytd","weight":0.0052}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江佐力药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38228人(较上一季度增加13.03%)","perCapita":"15771股","listingDate":"2011-02-22","address":"浙江省湖州市德清县阜溪街道志远北路388号","registeredCapital":"70138万元","survey":" 浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵胶囊、灵泽片、灵莲花颗粒、百令片、百令胶囊、中药饮片及中药配方颗粒、聚卡波非钙片。公司核心产品乌灵胶囊入选浙江省首批“浙产名药”、首批“浙产中药”产业品牌,入选由中国中医药循证医学中心发布的全国首批100个基于评价证据的中药品种目录。2024年2月,乌灵胶囊和灵泽片获评浙江省经济和信息化厅等八部门发布的首批“浙产中药”产业品牌名单。2024年3月,广东省交易控股集团指导,广东省药品交易中心主办的第九届中国药品交易年会召开,乌灵胶囊荣登“2023年最具影响力中成药产品十强榜”榜单。2024年5月,“强基层新征程”第十一届中国县域卫生发展大会召开,公司荣获2023-2024年度“赋能县域医疗高质量发展卓越品牌企业”,持续助力中国县域卫生发展。2024年6月,由米内网发起主办的“2023年度中国医药工业百强系列榜单”对外公布,公司位列“2023年度中国医药工业百强系列榜单”子榜单“2023年度中国中药企业TOP100排行榜”第48名。2024年6月,浙江省经济和信息化厅发布了《2023年度浙江省生物医药产业重点企业名单(领军型和高成长型)》,公司荣获“浙江省生物医药产业领军型企业”称号。2024年7月,由中国非处方药物协会、中国医药新闻信息协会与新华大健康联合主办的“中国第七届OTC品牌宣传月”启动,乌灵胶囊入选“中国第七届OTC品牌宣传月”宣传品牌。2024年8月,由中康科技主办的第十七届西普会,乌灵胶囊荣登2024年健康产业品牌榜,获得“西普金奖”。2024年11月,第三届泰山医药论坛暨2023-2024年度医药行业信息发布会召开,公司荣获2023-2024年度医药行业增长率前五十家企业和2023-2024年度制药工业营业收入前百家企业两项奖项。2024年11月,由家庭医生在线发起“2023-2024家庭常备药、家庭常备营养保健品、家庭常备医疗器械及消毒用品上榜品牌”颁奖典礼,乌灵胶囊荣登“家庭常备安神助眠药”“家庭常备老年认知障碍用药”及“家庭常备增强记忆用药”三大品牌榜单,并荣获最佳人气奖称号。2024年12月,由中国非处方药物协会主办的以“相信品牌的力量”为主题的第二届OTC品牌大会召开,乌灵胶囊荣获“2024年度中国非处方药黄金大单品”“中成药•头痛失眠类第二名”重要奖项。","listedPrice":23.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佐力药业,300181,佐力药业股票,佐力药业股票老虎,佐力药业股票老虎国际,佐力药业行情,佐力药业股票行情,佐力药业股价,佐力药业股市,佐力药业股票价格,佐力药业股票交易,佐力药业股票购买,佐力药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}